Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma - Reply

JAMA

Volumn 305, Issue 8, 2011, Pages 781-

  Abou Alfa, Ghassan ^a   Capanu, Marinela ^a   Saltz, Leonard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; PLACEBO; SORAFENIB;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; DRUG EFFICACY; HUMAN; LETTER; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 79951991175     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.160     Document Type: Letter

References (4)

1. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
2. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97(20):1532-1538. (Pubitemid 41631953)
3. Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007;25(21):3069-3075.
4. Llovet JM, Di Bisceglie AM, Bruix J, et al; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698-711.